TYPE: Prescription

BRAND: Montelukast/Montelukast Paediatric

ACTIVE INGREDIENT: Montelukast

STRENGTH, PACK SIZE & GMS CODES:

Montelukast Paediatric 4mg Chewable Tablets x 28’s ~ 45152

Montelukast Paediatric 5mg Chewable Tablets x 28’s ~ 45153

Montelukast 10mg Film-Coated Tablets x 28’s ~ 45154

 

INDICATION:

4mg Chewable Tablets (paediatric):

Montelukast is indicated in the treatment of asthma as add-on therapy in those
2 to 5 year old patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom “as-needed” short acting beta agonists provide inadequate clinical control of asthma. Montelukast may also be an alternative treatment option to low-dose inhaled corticosteroids for 2 to 5 year old patients with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids. Montelukast is also indicated in the prophylaxis of asthma from 2 years of age and older in which the predominant component is exercise-induced bronchoconstriction.

5mg Chewable Tablets (paediatric): 

Montelukast Paediatric is indicated in the treatment of asthma as add-on therapy in those 6 to 14 year old patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom “as-needed” short-acting beta-agonists provide inadequate clinical control of asthma.

Montelukast Paediatric may also be an alternative treatment option to low-dose inhaled corticosteroids for 6 to 14 year old patients with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids. Montelukast Paediatric is also indicated in the prophylaxis of asthma for 6 to 14 year old patients in which the predominant component is exercise-induced bronchoconstriction.

10mg Film-Coated Tablets:

Montelukast is indicated in the treatment of asthma as add-on therapy in adolescents and adults from 15 years of age with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom “as-needed” short acting beta-agonists provide inadequate clinical control of asthma. In those asthmatic patients in whom Montelukast is indicated in asthma, Montelukast can also provide symptomatic relief of seasonal allergic rhinitis.

Montelukast is also indicated in the prophylaxis of asthma in which the predominant component is exercise-induced bronchoconstriction.

 

Download Montelukast Paediatric 4mg SPC & PIL here

Download Montelukast Paediatric 5mg SPC & PIL here

Download Montelukast 10mg SPC & PIL here